Zhaoliang Su
- Immunology top 2%
- Molecular Biology top 5%
- Oncology top 5%
- Cancer Research top 5%
- Epidemiology top 10%
- Co-authors
- Huaxi XuShengjun WangHaitao ZhuPrince Amoah BarnieYanfang LiuJie WanJianguo ChenDinesh Kumar Kesavan
- Topics
- IL-33, ST2, and ILC Pathways (22 papers)Advanced Glycation End Products research (22 papers)Immune Response and Inflammation (18 papers)
- Journals
- SHILAP Revista de lepidopterologíaEnvironmental Science & TechnologyThe Journal of Immunology
In The Last Decade
Zhaoliang Su
151 papers receiving 3.6k citations
Peers
Comparison fields: 5 of 124
- Immunology 1.4k
- Molecular Biology 1.3k
- Oncology 564
- Cancer Research 498
- Epidemiology 414
Countries citing papers authored by Zhaoliang Su
This map shows the geographic impact of Zhaoliang Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhaoliang Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhaoliang Su more than expected).
Fields of papers citing papers by Zhaoliang Su
This network shows the impact of papers produced by Zhaoliang Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhaoliang Su. The network helps show where Zhaoliang Su may publish in the future.
Co-authorship network of co-authors of Zhaoliang Su
This figure shows the co-authorship network connecting the top 25 collaborators of Zhaoliang Su. A scholar is included among the top collaborators of Zhaoliang Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhaoliang Su. Zhaoliang Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 2 | |
| 3 | 0 | |
| 4 | 7 | |
| 5 | 8 | |
| 6 | 0 | |
| 7 | 3 | |
| 8 | 12 | |
| 9 | 10 | |
| 10 | 3 | |
| 11 | 17 | |
| 12 | 33 | |
| 13 | 12 | |
| 14 | 56 | |
| 15 | 2 | |
| 16 | 47 | |
| 17 | Drug resistance and transposon and insertion sequence of multi-drug resistant Acinetobacter baumannii. | 1 |
| 18 | 20 | |
| 19 | 83 | |
| 20 | Isolation and Identification of Flocculant-producing Pseudomonas sp.and Study on Properties of Flocculant | 1 |
About Zhaoliang Su
Zhaoliang Su is a scholar working on Immunology, Clinical Biochemistry and Molecular Medicine, having authored 159 papers that have together received 3.7k indexed citations. Recurring topics across this work include IL-33, ST2, and ILC Pathways (22 papers), Advanced Glycation End Products research (22 papers) and Immune Response and Inflammation (18 papers). The work is most often cited by research in Immunology (1.4k citations), Clinical Biochemistry (413 citations) and Cancer Research (498 citations). Zhaoliang Su has collaborated with scholars based in China, Canada and Hong Kong. Frequent co-authors include Huaxi Xu, Shengjun Wang, Haitao Zhu, Prince Amoah Barnie, Yanfang Liu, Jie Wan, Jianguo Chen, Dinesh Kumar Kesavan, Wei Cai and Zheng Dong. Their work appears in journals such as SHILAP Revista de lepidopterología, Environmental Science & Technology and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.